Drug Profile
Research programme: cancer immunotherapies - Fudan University/HUYA Bioscience International
Latest Information Update: 01 Sep 2023
Price :
$50
*
At a glance
- Originator Fudan University
- Class Antineoplastics
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer